Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Goodwill & Intangibles (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Goodwill & Intangibles for 4 consecutive years, with $407000.0 as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 23.78% to $407000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $407000.0 through Dec 2025, down 23.78% year-over-year, with the annual reading at $407000.0 for FY2025, 23.78% down from the prior year.
  • Goodwill & Intangibles hit $407000.0 in Q4 2025 for NewAmsterdam Pharma, down from $439000.0 in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $84.8 million in Q4 2022 to a low of $170000.0 in Q4 2023.
  • Historically, Goodwill & Intangibles has averaged $8.9 million across 4 years, with a median of $494000.0 in 2024.
  • Biggest five-year swings in Goodwill & Intangibles: crashed 99.8% in 2023 and later surged 214.12% in 2024.
  • Year by year, Goodwill & Intangibles stood at $84.8 million in 2022, then plummeted by 99.8% to $170000.0 in 2023, then soared by 214.12% to $534000.0 in 2024, then dropped by 23.78% to $407000.0 in 2025.
  • Business Quant data shows Goodwill & Intangibles for NAMS at $407000.0 in Q4 2025, $439000.0 in Q3 2025, and $470000.0 in Q2 2025.